Please check your internet connection and try again.
# Tabgenixim (Cefixime)
## Overview
Tabgenixim is a brand name for **Cefixime**, a third-generation oral cephalosporin antibiotic. It exhibits broad-spectrum activity against Gram-negative organisms (e.g., *Haemophilus influenzae*, *Moraxella catarrhalis*, *Neisseria gonorrhoeae*) and some Gram-positive activity, though it is less effective than first-generation cephalosporins against *Staphylococcus aureus* or *Streptococcus pneumoniae*.
## Primary Indications
* Uncomplicated urinary tract infections (UTIs)
* Otitis media
* Pharyngitis and tonsillitis
* Acute bronchitis and acute exacerbations of chronic bronchitis
* Uncomplicated gonorrhea (cervical/urethral/rectal)
## Adult Dosing
* **Respiratory/UTI/Pharyngitis:** 400 mg daily, administered either as a single dose or in two divided doses of 200 mg every 12 hours.
* **Uncomplicated Gonorrhea:** 800 mg orally as a single dose.
## Pediatric Dosing
* **Children (>6 months or >50 kg):** 8 mg/kg/day, administered as a single daily dose OR divided into 4 mg/kg every 12 hours.
* **Maximum:** 400 mg daily.
* **Note:** Use weight-based dosing for patients <50 kg.
## Dose Adjustments
* **Renal Impairment:**
* CrCl 21–60 mL/min: Reduce dose by 25% (or 75% of standard dose).
* CrCl <20 mL/min: Reduce dose by 50% (or 50% of standard dose).
* **Hepatic Impairment:** No standard dosage adjustment established.
## Contraindications
* Known hypersensitivity to cefixime, other cephalosporins, or components of the formulation.
* History of severe allergic reactions (e.g., anaphylaxis) to penicillins (due to the potential for cross-reactivity).
## Adverse Effects
* **Gastrointestinal:** Diarrhea (very common), nausea, abdominal pain, dyspepsia.
* **Hypersensitivity:** Rash, urticaria, drug fever, pruritus.
* **Rare but serious:** *Clostridioides difficile*-associated diarrhea (CDAD), anaphylaxis, Stevens-Johnson syndrome, hemolytic anemia.
## Key Drug Interactions
* **Warfarin:** May increase INR and bleeding risk due to alteration of gut flora interfering with Vitamin K synthesis.
* **Probenecid:** May increase serum concentration of cefixime by inhibiting renal excretion.
* **Aminoglycosides:** Potential for increased nephrotoxicity (rare).
## Monitoring
* Monitor for resolution of infection symptoms.
* Assess for signs of *C. difficile* infection (persistent diarrhea, abdominal cramping).
* Assess for hypersensitivity reactions during initial dosing.
* In long-term therapy, monitor renal and hepatic function.
## Clinical Pearls
* **Formulation:** Cefixime is available as tablets, chewable tablets, and oral suspension.
* **Absorption:** Presence of food does not significantly impact absorption.
* **Spectrum:** It is generally **not** appropriate for empiric treatment of *S. aureus* skin infections or pneumonia caused by susceptible *S. pneumoniae*.
* **Gonorrhea:** Due to the emergence of resistant *Neisseria gonorrhoeae*, local susceptibility patterns and current CDC treatment guidelines should be consulted; combination therapy (e.g., with azithromycin or doxycycline) is frequently required.
***
**Educational Disclaimer:** This information is for educational purposes only. Cefixime dosing and indications may vary based on local antimicrobial stewardship protocols, regional resistance patterns, and specific manufacturer labeling. Always verify current prescribing information and drug monographs before clinical application.
